1921
Volume 84, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniais (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Perprotocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment ( = 0.0001, 95% confidence interval [CI] = 0.190 [0.079–0.456]/ = 0.0051, 95% CI = 0.317 [0.140–0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment ( = 0.0003, 95% CI = 0.228 [0.098–0.528]/ = 0.0132, 95% CI = 0.382 [0.177–0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2011.10-0002
2011-04-05
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/84/4/539.html?itemId=/content/journals/10.4269/ajtmh.2011.10-0002&mimeType=html&fmt=ahah

References

  1. Talari SA, Talaei R, Shajari G, Vakili Z, Taghaviardakani A, , 2006. Childhood cutaneous leishmaniasis: report of 117 cases from Iran. Korean J Parasitol 44: 355360.[Crossref]
  2. Palacios R, Osorio LE, Grajalew LF, Ochoa MT, , 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 64: 187193.
  3. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG, , 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 195: 602608.[Crossref]
  4. Shahbazi F, Shahabi S, Kazemi B, Mohebali M, Abadi AR, Zare Z, , 2008. Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. Parasitol Res 103: 11591162.[Crossref]
  5. Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour A, , 1998. Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994–95. Bull World Health Organ 76: 289293.
  6. Kafetzis DA, , 2003. An overview of paediatric leishmaniasis. J Postgrad Med 49: 3138.[Crossref]
  7. Minodier P, Noel G, Blanc P, Uters M, Retornaz K, Garnier JM, , 2005. Management of cutaneous leishmaniasis in adults and children. Med Trop 65: 487495.
  8. Stavropoulos PG, Papakonstantinou AM, Petropoulou H, Kontochristopoulos G, Katsambas A, , 2006. Cryotherapy as an adjunct to systemic antimonials for cutaneous leishmaniasis in children. J Eur Acad Dermatol Venereol 20: 765766.[Crossref]
  9. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y, , 2006. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 142: 15751579.
  10. Tallab TM, Bahamdam KA, Mirdad S, Johargi H, Mourad MM, Ibrahim K, el Sherbini AH, Karkashan E, Khare AK, Jamal A, , 1996. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 35: 594597.[Crossref]
  11. Esfandiarpour I, Alavi A, , 2002. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 41: 521524.[Crossref]
  12. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M, , 2006. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 3: e162.[Crossref]
  13. Faghihi G, Tavakoli-kia R, , 2003. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 28: 1316.[Crossref]
  14. Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T, , 2009. Efficacy of cryotherapy versus intralesional meglumine antimoniate (Glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg 80: 172175.
  15. Chulay JD, Fleckenstein L, Smith DH, , 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 82: 6972.[Crossref]
  16. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE, , 2003. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 349: 11571167.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.10-0002
Loading
/content/journals/10.4269/ajtmh.2011.10-0002
Loading

Data & Media loading...

  • Received : 02 Jan 2010
  • Accepted : 26 Jan 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error